British drug maker, AstraZeneca, announced their late-stage clinical trial data shows their new antibody treatment, AZD7442, reduces the risk of developing COVID-19 symptoms by 77%. The study gives hope to sufferers whose immune system did not generate a strong...
The US Food and Drug Administration (FDA) has rejected Tenapanor for Control of Phosphorus in Kidney Disease, asking for another clinical trial that indicates the drug’s greater benefits before approval. Ardelyx devleoped Tenapanor, an oral inhibitor of the...
Johnson & Johnson have announced that findings from a laboratory study have shown promising results for it its single-dose COVID-19 vaccine against the Delta variant. Blood analysis drawn from eight patients revealed that immune responses to the Delta variant were...
The National Institute for Health and Care Excellence (NICE) originally rejected global biopharmaceutical company AstraZeneca’s lung cancer therapy Tagrisso (Osimertinib), but has since decided to reverse its initial decision. NICE initially did not recommend Tagrisso...
COVID-19 has forced most of the world to work remotely, causing a major disruption in clinical research and the drug development process. As a result, the need for centralized and advanced patient engagement technology to better healthcare for all parties involved,...
